Login / Signup

Randomised study of PF-06410293, an adalimumab (ADL) biosimilar, compared with reference ADL for the treatment of active rheumatoid arthritis: results from weeks 26-52, including a treatment switch from reference ADL to PF-06410293.

Roy M FleischmannDaniel F AlvarezAmy E BockCarol CronenbergerIvana VranicWuyan ZhangRieke E Alten
Published in: RMD open (2021)
ClinicalTrials.gov identifier: NCT02480153; EudraCT number: 2014-000352-29.
Keyphrases
  • rheumatoid arthritis
  • clinical trial
  • randomized controlled trial
  • open label
  • combination therapy
  • ankylosing spondylitis